This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
DMK Pharmaceuticals Beheer
Beheer criteriumcontroles 0/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Eddie Glover
Algemeen directeur
n/a
Totale compensatie
Percentage CEO-salaris | n/a |
Dienstverband CEO | no data |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | geen gegevens |
Gemiddelde ambtstermijn bestuur | geen gegevens |
Recente managementupdates
Recent updates
Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure
Sep 30Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.
Jul 29Adamis CEO urges stock split approval, slate of directors in letter to shareholders
Jul 21Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope
Apr 13Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic
Jan 20Adamis Pharmaceuticals: It's Now Or Never
Dec 02Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines
Sep 03Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares
Jun 13Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19
Jun 07Adamis pharmaceuticals gets deficiency letter from NASDAQ
May 28Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering
Jan 29Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose
Nov 16Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue
Nov 09CEO
Eddie Glover (74 yo)
no data
Tenure
Mr. Eddie Wabern Glover serves as Chief Executive Officer of US Compounding Inc at DMK Pharmaceuticals Corporation (formerly known as Adamis Pharmaceuticals Corporation). He co-founded US Compounding, Inc....